Bilal Siddiqui

18PUBLICATIONS
96CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Neurology and neuromuscular diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 22, 2026
Key regulatory elements of the TGFβ-LRRC15 axis predict disease progression and immunotherapy resistance across cancer types.

|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

|May 07, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

|Feb 24, 2026
The path forward for T cell engagers in patients with prostate cancer.

Sumit K Subudhi, Bilal A Siddiqui, Kevin K Zarrabi

|Nov 07, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy.

Neha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida

|Jul 21, 2025
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier

Pageof 3

Frequent Collaborators

5 joint publications

Sumit K Subuhdi

4 joint publications

Sreyashi Basu

3 joint publications

Rebecca S Slack-Tidwell

2 joint publications

Shalini S Yadav